Immunovant, Inc. (IMVT) — Stock Score Summary

Immunovant, Inc. (IMVT) has a MoatMap StockRank of 54/100 based on Quality (38/100), Value (35/100), and Momentum (67/100) factor scores. The current signal is HOLD. Immunovant is a clinical-stage immunology biotech with high cash burn and no current revenues, making it a speculative asset that violates our Terry Smith quality compounder rules.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapies for patients with autoimmune diseases. The company's lead investigational product, batoclimab, is a novel FcRn inhibitor designed to reduce pathogenic IgG antibodies that drive a broad range of autoimmune conditions. Its competitive position hinges on the potential for batoclimab to become a best-in-class treatment across multiple indications with high unmet medical needs.

Key Financial Metrics

Price$31.61
Market Cap$6.9B
P/E (Forward)-13.41
Price/Book7.81
Return on Equity-64.8%
Return on Invested Capital-61.9%
Debt/Equity0.01
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-234M

Immunovant, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Immunovant, Inc.’s (IMVT) StockRank?
MoatMap’s StockRank for Immunovant, Inc. (IMVT) is 54/100, with a Hold signal. It is a composite of Quality (38), Value (35), and Momentum (67) factor ranks across MoatMap’s 19,000+ stock universe.
Does Immunovant, Inc. have an economic moat?
Immunovant, Inc. (IMVT) has a Quality factor score of 38/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Immunovant, Inc. a buy, hold, or sell?
MoatMap’s current signal for Immunovant, Inc. (IMVT) is Hold, based on a StockRank of 54/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Immunovant, Inc. in?
Immunovant, Inc. (IMVT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksIMVT deep dive reportAI ChampionsHow we score stocksSense-check another stock